Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
February 29, 2024 08:30 ET
|
Intercept Pharmaceuticals, Inc.
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as...
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
November 13, 2023 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first...
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
November 10, 2023 08:00 ET
|
Intercept Pharmaceuticals, Inc.
New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULN Findings suggest that OCA has the potential to reduce the liver biomarker GGT, in addition to...
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
November 08, 2023 09:13 ET
|
Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the...
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
September 26, 2023 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. marketTransaction price represents an 82% premium to...
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
September 05, 2023 08:30 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 02, 2023 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarterCompany updates full-year 2023 Ocaliva net sales guidance to $320 million to $340...
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
June 23, 2023 06:30 ET
|
Intercept Pharmaceuticals, Inc.
Measures reinforce Company’s ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by...
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
June 23, 2023 02:45 ET
|
Intercept Pharmaceuticals, Inc.
Planned interim analysis from the first of two Phase 2 studies shows combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in...